Emend and Respiratory disorder - a phase IV clinical study of FDA data

Summary:

Respiratory disorder is reported as a side effect among people who take Emend (aprepitant), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Remicade, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Respiratory disorder when taking Emend. It is created by eHealthMe based on reports of 13,708 people who have side effects when taking Emend from the FDA, and is updated regularly.

What is Emend?

Emend has active ingredients of aprepitant. It is often used in nausea. eHealthMe is studying from 13,741 Emend users. Check the latest studies of Emend.

What is Respiratory disorder?

Respiratory disorder (respiratory disease) is found to be associated with 1,540 drugs and 1,583 conditions by eHealthMe. Check the latest studies of Respiratory disorder.

On Jul, 11, 2026

13,708 people reported to have side effects when taking Emend.
Among them, 49 people (0.36%) have Respiratory disorder.

Among these 49 people:

How long have people been on Emend when they have Respiratory disorder? *

What is the gender of people who have Respiratory disorder when taking Emend? *

female: 81.4 %
male: 18.6 %

What is the age of people who have Respiratory disorder when taking Emend? *

What are other drugs people take besides Emend? *

What are other side effects people have besides Respiratory disorder? *

Dyspnea (difficult or laboured breathing): 37 people, 75.51%
Hypersensitivity: 34 people, 69.39%
Wheezing (a high-pitched whistling sound made while you breath): 33 people, 67.35%
Infusion Related Reaction: 31 people, 63.27%
Nasopharyngitis (inflammation of the nasopharynx): 30 people, 61.22%
Hair Loss: 30 people, 61.22%
Pain: 30 people, 61.22%
Hand Deformity: 30 people, 61.22%
Headache (pain in head): 30 people, 61.22%
Night Sweats (sweating in night): 30 people, 61.22%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 30 people, 61.22%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 23 people, 46.94%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 23 people, 46.94%
Psoriasis (immune-mediated disease that affects the skin): 20 people, 40.82%
Ankylosing Spondylitis (type of arthritis affecting the spine): 15 people, 30.61%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 9 people, 18.37%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 4 people, 8.16%
Synovitis (inflammation of the synovial membrane): 3 people, 6.12%
Pain: 3 people, 6.12%
Fever: 3 people, 6.12%

* Approximation only. Some reports may have incomplete information.

Do you take Emend and have Respiratory disorder?

- Check whether Respiratory disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Emend:

Emend (13,741 reports)

Browse all side effects of Emend:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Respiratory disorder:

Respiratory disorder (1,540 drugs)

Browse all the conditions that are associated with Respiratory disorder:

Respiratory disorder (1,583 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on aprepitant (the active ingredients of Emend) and Emend (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.